Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
puyisita mesylate
- Development stage
- Phase 1
- Lead developer
- Guizhou Bailing Group Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Puyisita mesylate (PTS-02) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor developed by Guizhou Bailing Enterprise Group Pharmaceutical. As a Class 1.1 innovative drug in China, it is designed to treat various hematologic malignancies by inhibiting HDAC enzymes, which are involved in the epigenetic regulation of gene expression. Inhibition of these enzymes leads to increased histone acetylation, chromatin remodeling, and the induction of cell cycle arrest and apoptosis in cancer cells. Puyisita mesylate is currently being evaluated in Phase 1 and Phase 2 clinical trials for indications such as relapsed or refractory B-cell non-Hodgkin's lymphoma, multiple myeloma, and acute lymphoblastic leukemia.
- Other names
- puyisita普依司他PTS-02 mesylatePTS02 mesylatePTS 02 mesylate
02
Targets
HDAC (HDAC family)
Beyond the preview
Go deeper on puyisita mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on puyisita mesylate.